

hydrolysis of the substrate to para-nitrophenol and result in formation of a yellow color. The reaction is then stopped and the color read with a photometer at 405 nm (reference at 600-630 nm). The intensity of the color developed is proportional to the concentration of anti-Scl-70 IgG present in the sample.

## SUMMARY OF PROCEDURE

1. Prepare a 1:101 dilution of samples in Sample Diluent. Mix well.
2. Add 100 µl of diluted samples into the antigen wells. Reserve one well for reagent blank (100 µl of Sample Diluent).
3. Incubate at room temperature (18 - 30° C) for 30 ± 5 min.
4. Discard contents of the wells. Wash the wells 3 times with Wash Solution.
5. Add 100 µl of Conjugate to each well.
6. Incubate at room temperature for 30 ± 5 min.
7. Wash the wells as in #4 above.
8. Add 100 µl Substrate Solution to each well.
9. Incubate at room temperature for 30 ± 5 min.
10. Add 100 µl Stop Solution to each well.
11. Read the absorbance at 405 nm (reference at 600 - 630 nm) against the reagent blank.

## INTENDED USE

For the detection and semi-quantitation of antibodies against the Scl-70 antigen in serum as an aid in the diagnosis of autoimmune disease.

## SUMMARY AND EXPLANATION

Systemic rheumatic disease is characterized by the presence of circulating autoantibodies that are widely reactive with both nuclear and cytoplasmic antigens. Systemic sclerosis (scleroderma) is a chronic disease of unknown etiology which affects connective tissue and small arteries. It is characterized by fibrotic and degenerative changes in the skin, blood vessels, and internal organs.<sup>1,3</sup>

Two major subtypes of scleroderma have been recognized. Diffuse scleroderma is a rapidly progressive form of the disease characterized by widespread changes in the skin, the distal and proximal extremities, the trunk and the viscera. The second type is limited scleroderma, also known as CREST (*Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasis*) syndrome. In this milder form of the disease, skin involvement is limited to the fingers, hands, or face and involvement of the internal organs can be delayed for years.<sup>2,3</sup>

Two autoantibodies have been identified which are present almost exclusively in scleroderma.<sup>4</sup> The first of these is the anti-Scl-70 antibody, which has been identified as antibody to the nuclear enzyme, topoisomerase I. Antibodies to Scl-70 are present in approximately 20-33% of patients with scleroderma, but are rarely seen in patients with other connective tissue disorders.<sup>4,5</sup> The second autoantibody, anti-centromere, is strongly associated with limited scleroderma or CREST syndrome. In addition, from 4 to 18% of CREST have anti-topoisomerase I (anti-Scl-70) antibodies.<sup>4,5</sup> The detection of either of these autoantibodies permits a high degree of certainty in the diagnosis of scleroderma and can aid in differentiating the scleroderma subtypes.<sup>4</sup>

Until recently, many laboratories used fluorescent antinuclear antibody (FANA) and Immunodiffusion (ID) to detect anti-Scl-70 antibodies. However, neither of these methods is quantitative and their sensitivity, reproducibility, cost-effectiveness, and ease of performance are poor and variable. Enzyme immunoassay (EIA) has advantages over the ID method in sensitivity, specificity, ease of automation, and testing turnaround time.<sup>6</sup>

The Diamedix *Is-anti-Scl-70* Test Kit is an EIA procedure intended for the semi-quantitation of antibodies to Scl-70 antigen. The results are reported in ELISA units (EU) per ml determined by comparison to a Calibrator.

## PRINCIPLE OF THE PROCEDURE

Purified Scl-70 antigen from bovine spleen and/or thymus is bound to microwells. Diluted patient sera, Calibrator, and controls are placed in the microwells and incubated. Anti-Scl-70 antibodies, if present, will bind to the antigen in the microwells. After washing the microwells to remove unbound antibodies, a second incubation with anti-human IgG conjugated to alkaline phosphatase is carried out. The conjugate will bind to human anti-Scl-70 antibodies, if present, forming an immunocomplex. The microwells are then washed again to remove unbound components and the enzyme substrate, para-nitrophenylphosphate is added. The enzyme, if bound, will catalyze the

## REAGENTS

**Each *Is-anti-Scl-70* Kit contains reagents for 96 tests.**

Antigen Wells	Twelve, 8-well microwell breakapart strips, color-coded silver, coated with Scl-70 antigen.
Calibrator	One vial with blue cap containing 0.25 ml of human serum, 0.1% sodium azide. Assigned value printed on label.
Negative Control	One vial with black cap containing 0.25 ml of non-reactive human serum, 0.1% sodium azide.
Positive Control	One vial with white cap containing 0.25 ml of reactive human serum, 0.1% sodium azide. Assigned range printed on label.
Sample Diluent	One bottle with blue cap containing 60 ml Phosphate buffer with protein stabilizers. Contains Proclin® 300, 15 ppm active ingredient. Color-coded blue.
Wash Concentrate (20X)	Two bottles with clear caps containing 50 ml of Phosphate buffer with detergent and Proclin® 300, 15 ppm active ingredient. Each bottle is sufficient to make 1050 ml of wash solution.
Conjugate	One bottle with red cap containing 25 ml goat anti-human immunoglobulin G labeled with alkaline phosphatase. Also includes protein stabilizers and Proclin® 300, 30 ppm active ingredient. Color-coded pink.
Substrate	One amber bottle with brown cap containing 25 ml para-Nitrophenyl phosphate in a buffered solution. <i>Substrate solution may develop a slight yellow color upon storage.</i>
Stop Solution	One bottle with white cap containing 25 ml. Sodium phosphate, tribasic. CAUTION: Solution is caustic. Avoid contact with skin. If contact is made, flush area with copious amounts of water.

**Store these reagents at 2 to 8° C.**

## OTHER MATERIALS REQUIRED

### Manual Users:

Wash bottle or automated microplate washer  
Pipettors capable of dispensing appropriate volumes  
Timer  
One liter graduated cylinder  
One liter wash solution reservoir  
Deionized or distilled water  
Absorbent toweling  
Tubes or microwell plate for serum dilution  
Reader capable of reading absorbance at 405 nm, reference at 600 or 630 nm.

### Automated EIA Processor Users:

One liter graduated cylinder  
Deionized or distilled water  
Pre-dilution cups, strips or plates.  
ProbeClean™ Concentrate, or tip washing detergent solution, if applicable.

## PRECAUTIONS

1. Handle samples, calibrators, controls and the materials that contact them as potential biohazards. Each donor unit in the Calibrator and controls has been found negative for Hepatitis B surface antigen and HIV-I antibodies by FDA-approved third generation tests. However, because no method can offer complete assurance that HIV-1, Hepatitis B virus, or other infectious agents are absent, these materials should be handled at the Biosafety Level 2 as recommended for any potentially infectious serum or blood specimen in the Centers for Disease

Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories", 1988.

- Never pipette by mouth.
- Avoid contact with open skin.
- Certain of the test reagents contain Proclin® 300 as a preservative. When disposing of reagents containing Proclin® 300, flush drains with copious amounts of water to dilute the active components below active levels.

- Reagents containing Sodium Azide:

(a) **CAUTION:** Some reagents in this kit contain Sodium Azide as preservative. Sodium Azide may react with lead or copper plumbing to form highly explosive metal azides. On disposal, flush with a large volume of water to prevent azide build-up. For further information, refer to "Decontamination of Laboratory Sink Drains to Remove Azide Salts", in the Manual Guide – Safety Management No. CDC-22, issued by the Centers for Disease Control and Prevention, Atlanta, GA, 1976.

#### European Communities Hazardous Substance Risk Phrases (Regulation (EC) No 1272/2008)

H300 –Fatal if swallowed.

H310 – Fatal if contact with skin.

H314 – Contact with acids liberates very toxic gas.

H410 – Very toxic to aquatic life with long lasting effect.

P264 – Wash all exposed external body areas thoroughly after handling.

P302+P352 – IF ON SKIN: Wash with plenty of water and soap.

P301+P310/P330 – IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. Rinse mouth.

P270 – Do not eat, drink or smoke when using this product.

P501 – Dispose of contents/container as hazardous waste.

P391 – Collect spillage.

P273 – Avoid release to the environment. Refer to special instructions/ Safety Data Sheet.

(b) Sodium Azide inhibits horseradish peroxidase activity. Care must be taken to ensure that azide is not carried over from other reagents into conjugate and substrate steps.

#### RECOMMENDATIONS FOR LABORATORY QUALITY CONTROL

- Do not mix or interchange wells, controls, or calibrators from different lots.
- Do not use reagents beyond their expiration date. Expiration dates are printed on the reagent labels.
- Incubations above or below the recommended temperatures or times may give erroneous results.
- The ELISA method is a very sensitive technique. Maintain consistent pipetting technique, incubation times, and temperature conditions throughout the test procedure. Cross contamination between reagents can invalidate the test.
- Antigen coated microwells should be stored with the desiccant in the resealable bag provided and returned to the refrigerator immediately after use.
- (Manual Procedure Only) The washing procedure is very important and requires special attention. (Please refer to the Procedure section)

**NOTE:** Improperly washed wells may give erroneous results.

#### SPECIMEN COLLECTION

Whole blood should be collected by accepted medical techniques. The serum is separated from the clot and refrigerated at 2 to 8°C for short-term storage (up to 7 days), or stored frozen at -20°C for long term storage. Avoid multiple freeze-thaw cycles. Specimens containing visible particulate matter should be clarified by centrifugation before testing. Grossly contaminated, hemolyzed, lipemic, or icteric specimens should not be used.

**CAUTION:** Serum samples must not be heat-inactivated prior to use.

#### PROCEDURE

Allow all test components and patient samples to warm to room temperature before use. Invert reagent bottles gently several times before use. Return promptly to the refrigerator after use.

Prepare Wash Solution by adding 50 ml of Wash Concentrate (20X) to one liter of deionized or distilled H<sub>2</sub>O.

#### Manual Users:

- Prepare 1:101 dilutions of the calibrator, controls, and patient samples in Sample Diluent. (e.g., by addition of 2 µl sample to 200 µl Sample Diluent or 5 µl sample to 500 µl Sample Diluent)
- Mix sample dilutions gently by withdrawing and expelling in a pipette tip 2 or 3 times or by vortex mixing for 2 or 3 seconds. Transfer 100 µl of diluted calibrator, control, or patient sample, to the antigen wells. Avoid formation of bubbles when transferring diluted samples.  
**NOTE:** Include one well which contains 100 µl of Sample Diluent only as the reagent blank. This will ultimately be used to "zero" the photometer before reading the test results.
- Allow the wells to incubate at room temperature (18 - 30°C) for 30 ± 5 minutes.
- Aspirate or discard the contents of the wells. Remove any excess moisture in the wells by tapping on paper toweling if necessary. Wash the wells by rinsing 3 times with at least 300 µl per well of Wash Solution. Remove excess moisture from the wells after washing. When using an automated washer, follow the manufacturer's instructions.
- Place 100 µl of Conjugate into each well, avoiding bubble formation.
- Allow the wells to incubate uncovered at room temperature (18 - 30°C) for 30 ± 5 minutes.
- Wash the wells as described in Step 4 above.
- Place 100 µl of Substrate into each well, avoiding bubble formation.
- Allow the wells to incubate uncovered at room temperature (18 - 30°C) for 30 ± 5 minutes.
- Place 100 µl of Stop Solution into each well, avoiding bubble formation.
- Read the absorbance of each well at 405 nm and zero against the reagent blank. A suitable reference wavelength (e.g., 600-630 nm) reading should be used. Read the plate within 60 minutes of adding Stop Solution.

#### Automated EIA Processor Users:

If using an Automated EIA Processor, refer to the Operator's Manual for the test setup and procedures.

**NOTE:** Automated EIA Processor users must validate their equipment to demonstrate that the results obtained are equivalent to those obtained using manual assay.

#### RESULTS

##### Calculation Results

Determine the EU/ml (ELISA Units/ml) for each patient specimen or control using the following formula:

$$\frac{\text{EU/ml of Calibrator}}{\text{Absorbance of Calibrator}} \times \text{Absorbance of sample} = \text{EU/ml of sample}$$

##### Single Point Calibration

The Is-anti-Scl-70 Test Kit has been developed using a single point calibrator. Patient values, which contain very high levels of antibody may produce absorbance values greater than the Calibrator absorbance. Patient sample results greater than the Calibrator value should be reported as "Greater than Calibrator value EU/ml". If numerical results are required for such samples, dilute the sample using Sample Diluent and re-assay. Several dilutions (for example 1/10, 1/50 and 1/100) of the prediluted sample may be re-assayed simultaneously. Select the dilution that has an absorbance reading about 50% of the absorbance reading of the Calibrator; calculate the EU/ml for this dilution and multiply by the dilution factor to obtain estimated values.

##### Test Validation Criteria

- The Positive Control must be within its assigned range.
- The Negative Control must be < 16 EU/ml.
- The absorbance of the reagent blank must be < 0.30.

If any of these criteria is not met, the run is invalid and must be repeated.

## INTERPRETATION OF RESULTS

The following is a guide to interpretation of results. Each laboratory is encouraged to establish its own "normal" ranges based on populations encountered.

<i>Is-anti-Scl-70</i> Value	Index Value *	Interpretation
< 16 EU/ml	< 0.8	Negative for antibodies to Scl-70.
16-20 EU/ml	0.8 – 1.0	Equivocal for antibodies to Scl-70. Sample should be retested. If retest results are equivocal, the sample should be reported as equivocal, tested by another method, or a new sample should be tested. **
> 20 EU/ml	> 1.0	Positive for antibodies to Scl-70.

\* The Index Value is calculated by dividing the EU/ml of the sample by 20.

\*\* Equivocal samples that give positive results upon retest should be reported as positive. Equivocal samples that give negative results upon retest should be reported as negative.

## LIMITATIONS

1. The analysis of a single serum sample should not be used as the sole criterion for diagnosis of an autoimmune disease.
2. The results obtained with the *Is-anti-Scl-70* Test Kit serve only as an aid to diagnosis and should not be interpreted as diagnostic in themselves.
3. The test should be performed on serum. The use of whole blood or plasma has not been established.


## EXPECTED VALUES

Antibodies to Scl-70 are present in approximately 20-33% of patients with scleroderma.<sup>5</sup>


The expected values in the normal population were determined by assaying 100 normal donor sera collected in South Florida. Figures 1 and 3 show the distribution of Scl-70 results in the normal population performed manually and on MAGO respectively.

The distribution of EU/ml values for 63 clinically characterized sera along with the 100 normal donor sera is shown in Figures 2 and 4 performed manually and on MAGO respectively.


**FIGURE 1**  
Manual




**FIGURE 2**  
Manual



**FIGURE 3**  
MAGO  
*Is-anti-Scl-70* Normals



**FIGURE 4**  
MAGO  
*Is-anti-Scl-70* Expected Values



## PERFORMANCE CHARACTERISTICS

### A. Comparison Testing

The Diamedix *Is-anti-Scl-70* Test Kit was evaluated relative to another commercially available anti-Scl-70 ELISA test kit using clinically characterized sera. One hundred sera from normal blood donors and 63 sera from autoimmune patients were tested by the *Is-anti-Scl-70* Test Kit and a commercially obtained anti-Scl-70 ELISA test kit. Results are shown in Table 1.

**TABLE 1**

	Manual			MAGO		
	Number of Sera	%	95% Confidence	Number of Sera	%	95% Confidence
<b>Relative Sensitivity</b>	21/24	88	68-97	22/24	92	73-99
<b>Relative Specificity</b>	138/138	100	97-100	138/139	99	96-100
<b>Agreement</b>	159/162*	98	95-100	160/163	98	95-100

\* One equivocal sample was excluded from the calculations.

Three sera negative by *Is-anti-Scl-70* (manual) and positive by the comparative method were negative when tested by a third method. Two sera negative by *Is-anti-Scl-70* (MAGO) and positive by the comparative method were negative by a third method. One sample positive by *Is-anti-Scl-70* (MAGO) and negative by the comparative method was positive by a third method.

### B. Precision

The precision of the *Is-anti-Scl-70* Test Kit was determined by testing six different sera and kit Calibrator and controls in two runs on three different days. The intra- and interassay precision is shown in Table 2.


**TABLE 2**

SERUM	<i>Is</i> -anti- <i>Scl</i> -70 Precision				
	Overall	MANUAL		MAGO	
	MEAN EU/ml	INTRA-CV%	INTER-CV%	INTRA-CV%	INTER-CV%
1 (NEG)	2.3	5.7	8.7	18.3	18.2
2 (NEG)	3.9	5.8	10.3	12.4	13.2
3 (POS)	50.5	3.1	5.0	1.8	5.4
4 (POS)	29.0	4.3	4.4	5.3	9.4
5 (POS)	79.6	2.7	4.5	2.1	3.5
6 (POS)	103.1	4.8	3.6	4.7	6.1
CAL	106.0	5.4	7.3	3.3	6.7
POS CTRL	52.3	1.5	3.1	3.9	6.6
NEG CTRL	1.6	12.6	14.3	20.2	29.4


**C. Linearity**

Figures 5 and 6 show typical examples of *Is*-anti-*Scl*-70 Test Kit linearity. The figures depict the results of the Calibrator tested by *Is*-anti-*Scl*-70 after a serial two-fold manual dilution in Sample Diluent. Separate dilutions were tested both manually and with MAGO. The results demonstrate a high degree of linearity for the *Is*-anti-*Scl*-70 Test Kit throughout the testing range.

**FIGURE 5  
Manual**



**FIGURE 6  
MAGO**



**D. Crossreactivity**

Twenty-four sera positive for the six autoimmune specificities were tested in the *Is*-anti-*Scl*-70 Test Kit. The results are shown in Table 3.


**TABLE 3  
Crossreactivity**

Sample	<i>Is</i> -anti- <i>Scl</i> -70 EU/ml	Interp	Specificity	Sample	<i>Is</i> -anti- <i>Scl</i> -70 EU/ml	Interp	Specificity
1	7.2	NEG	SSA	13	4.4	NEG	RNP
2	3.7	NEG	SSA	14	3.0	NEG	RNP
3	1.5	NEG	SSA	15	4.2	NEG	RNP
4	3.0	NEG	SSA	16	4.7	NEG	RNP
5	4.0	NEG	SSB	17	3.3	NEG	Jo-1
6	2.6	NEG	SSB	18	5.1	NEG	Jo-1
7	3.1	NEG	SSB	19	1.9	NEG	Jo-1
8	3.6	NEG	SSB	20	2.9	NEG	Jo-1
9	3.0	NEG	Sm	21	134.2	POS	Scl-70
10	3.2	NEG	Sm	22	108.0	POS	Scl-70
11	2.5	NEG	Sm	23	110.1	POS	Scl-70
12	4.1	NEG	Sm	24	165.6	POS	Scl-70

**E. Correlation of Manual and MAGO Results**

Correlation of manual and MAGO EU/ml values for 163 samples tested in the *Is*-anti-*Scl*-70 Test Kit is shown in Figure 7.

**FIGURE 7  
*Is*-anti-*Scl*-70 Correlation of**



**REFERENCES**

1. Siebold, J. R. 1993. Connective Tissue Diseases Characterized by Fibrosis. In: Textbook of Rheumatology, Fourth Edition, W. B. Saunders Co., Philadelphia, p. 1113-1143.
2. Steen, V. D., Medsger, T. A., Ziegler, G. and Rodnan, G. P. 1980. Clinical comparison of two variants of progressive systemic sclerosis: Diffuse scleroderma and CREST syndrome. Arthritis Rheum. 23: 752.
3. Rodnan, G. P., Jablonska, S. and Medsger, T. A. 1979. Classification and Nomenclature of Progressive Systemic Sclerosis (Scleroderma). Clin. Rheum. Dis. 5: 5-13.
4. Steen, V. D., Powell, D. L. and Medsger, T. A. 1988. Clinical Correlations and Prognosis Based on Serum Autoantibodies in Patients with Systemic Sclerosis. Arthritis Rheum. 31: (2) 196-203.
5. Craft, J. and Hardin, J. A. 1993. Antinuclear Antibodies. In: Textbook of Rheumatology, Fourth Edition, W. B. Saunders Co., Philadelphia, p.164-187.
6. Engvall, E. and Perlmann, P. 1972. Enzyme-Linked Immunosorbent Assay, ELISA III. Quantitation of Specific Antibodies by Enzyme-Labeled Anti-Immunoglobulin in Antigen Coated Tubes. J. Immunol. 109: 129-135.
7. Manual Guide – Safety Management No. CDC – 22, “Decontamination of Laboratory Sink Drains to Remove Azide Salts”, Centers for Disease Control and Prevention, Atlanta, GA, April 30, 1976.

Proclin® 300 is a registered trademark of Rohm and Haas Corp. Philadelphia, PA.

Diamedix Corporation • A Subsidiary of ERBA Diagnostics, Inc.  
14100 NW 57th Court – Miami Lakes, Florida 33014 - USA  
(305) 324-2300 / (800) 327-4565  
www.erbadiagnostics.com

**EC REP** Delta Biologicals S.r.l., Via Nicaragua 12/14, 00071 - Pomezia, Rome Italy  
Telephone #: +39-06-91190.1 Fax #: +39-069105244



I-720-280  
Rev. 6 – June 15